Your session is about to expire
← Back to Search
Cetuximab for Lung Cancer
Study Summary
This trial is testing carboplatin, paclitaxel, bevacizumab, and cetuximab to treat patients with stage IV or recurrent non-small cell lung cancer.
- Large Cell Lung Carcinoma
- Lung Cancer
- Large Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
For what purpose is Bevacizumab most commonly prescribed?
"Bevacizumab is most frequently used to fight cancer, but it can also be employed as a treatment for conditions like locally advanced nonsquamous non-small cell lung cancer, intolerance to irinotecan, and metastatic colorectal cancer."
Does Bevacizumab have a good safety profile?
"Bevacizumab has been studied in multiple clinical trials, so its safety rating is a 3."
Are there any other similar studies to Bevacizumab that have been completed?
"City of Hope Comprehensive Cancer Center first studied bevacizumab in 1997 and, to date, there have been 3152 completed trials. Of these clinical studies, 1620 are active with many of them located in Silver Spring, Maryland."
Who else is applying?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
What state do they live in?
Share this study with friends
Copy Link
Messenger